

ADDENDUM TO 2019 PROGRESS REPORT

In compliance with the Better Business Bureau (BBB), ACGT is providing this addendum detailing Management/General and Fundraising Expenses. These expenses are underwritten by a separate fund so that 100% of public donations go directly to research and program.

ACGT FISCAL YEARS ENDED APRIL 30, 2019

CONDENSED STATEMENTS OF ACTIVITIES

2019

Support and revenue:

Contributions	\$837,594
Special events	321,717
Contributed services	538,010
Investment and other income	350,856
TOTAL SUPPORT AND REVENUE	2,048,177

Expenses:

Program services	1,913,613
Management and General	322,449
Fundraising	160,378
TOTAL EXPENSES	2,396,440
(Decrease) increase in total net assets	(348,263)
Total net assets at beginning of year	4,823,285

TOTAL NET ASSETS AT END OF YEAR

\$4,475,022

CONDENSED STATEMENTS OF FINANCIAL POSITION

Assets:

Cash and cash equivalents	\$733,247
Investments, at fair value	5,397,306
Contributions receivable	176,003
Other assets	45,877
TOTAL ASSETS	\$6,352,433

Liabilities and net assets:

Liabilities	
Grants payable	\$1,813,644
Accrued expenses	63,767
TOTAL LIABILITIES	1,877,411
TOTAL NET ASSETS	4,475,022

TOTAL LIABILITIES AND NET ASSETS

\$6,352,433

Alliance for Cancer Gene Therapy, Inc.'s complete financial statements are available upon request.